

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

5,000

Open access books available

125,000

International authors and editors

140M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.  
For more information visit [www.intechopen.com](http://www.intechopen.com)



# Platelet-Bacterial Interactions as Therapeutic Targets in Infective Endocarditis

Steven W. Kerrigan and Dermot Cox  
*Royal College of Surgeons in Ireland*  
Dublin,  
Ireland

## 1. Introduction

Endocarditis is an inflammation of the lining of the heart and valves. It can be due to a non-infectious cause (Asopa et al., 2007) but when the inflammation is associated with an infection, usually bacterial, it is known as infective endocarditis (IE) and is characterized by the development of a large septic thrombus on one of the cardiac valves (Beynon et al., 2006; Moreillon and Que, 2004). As this thrombus grows, it can lead to valve failure or may fragment forming a septic embolus that is associated with high mortality if the target of the embolus is the brain, heart or lung (Homma and Grahame-Clarke, 2003). Untreated the mortality is very high and even with aggressive therapy with antibiotics and valve replacement surgery there is a significant mortality. Primarily the disease is due to the formation of a platelet-bacteria thrombus on a cardiac valve and this review will look at the interaction between bacteria and platelets within the context of endocarditis.

## 2. Traditional role of platelets in thrombosis

Platelets are anucleate fragments of megakaryocytes and their primary role is in haemostasis. Damage to the endothelium surrounding blood vessels leads to the exposure of the sub-endothelial layer that is rich in collagen and immobilised plasma proteins such as von Willebrand factor (vWf). Platelets bind to the newly exposed collagen and become activated. Many blood vessels, such as the coronary arteries are high shear vessels and the blood is flowing too fast to allow the platelets to bind to the collagen. However, under these high shear conditions immobilised vWf can interact with platelet GPIb, which slows down the platelets allowing them to subsequently interact with collagen. Once activated platelets aggregate to form a thrombus which the damaged blood vessel. GPIIb/IIIa mediates platelet aggregation by binding plasma fibrinogen, which as a divalent protein can bind to two separate GPIIb/IIIa molecules. As a result, activated platelets are cross-linked by fibrinogen, which forms the aggregates that seal the damaged vessel.

Platelets are highly responsive and can be activated by many different agonists. As well as two different collagen receptors ( $\alpha 2\beta 1$  and GPVI) and two ADP receptors  $P_2X_1$  and  $P_2Y_{12}$ , a serotonin receptor, an adrenergic receptor and a thromboxane  $A_2$  receptor there are also three thrombin receptors (Protease-activated receptor (PAR)-1,  $GPIIb\alpha$  and PAR-4). Platelet

activation is dependent on the sum of the signals from all of these receptors and not on any specific receptor. Signalling from these receptors is either phospholipase A<sub>2</sub>/cyclooxygenase (COX)-mediated, resulting in the generation of thromboxane A<sub>2</sub>, or protein kinase C-mediated. In contrast, the generation of intracellular cAMP in response to prostacyclin binding to its receptor acts to inhibit platelet activation.

Aside from their ability to adhere to sites of damage and to form aggregates, platelets also secrete their granule contents in response to activation. Platelets contain three different granules:  $\alpha$ -granules, dense granules and lysosomes. Dense granules are rich in small molecules especially ATP/ADP and serotonin,  $\alpha$ -granules contain numerous plasma proteins typically associated with haemostasis and the lysosomes contain acid hydrolases. These secreted products act to enhance haemostasis as ADP activates other platelets, serotonin causes vasoconstriction and the secreted proteins support platelet aggregation.

### 3. The role of platelets in innate immunity

The biological role of platelets is not confined to haemostasis as platelets also play an important role in the innate immune system (Cox et al., 2011; Semple and Freedman, 2010). Platelets are ideally suited to this as they are present at very high concentration in the blood and are the first responders to any damage to the vasculature, which is the primary mechanism by which pathogens gain entry to the blood. To facilitate this, platelets contain surface receptors that allow it to respond to pathogens. Platelets contain pattern recognition receptors, especially Toll-like receptors (TLRs). These and other receptors (see below) allow platelets to respond to pathogens. As with other platelet agonists, platelets respond to pathogens by adhering to them and subsequently become activated leading to thrombus formation and secretion. In the context of the innate immune system, secretion is the primary response. Activated platelets secrete anti-microbial peptides that act to kill bacteria (Mercier et al., 2004). They also secrete cytokines such as CD40L and RANTES (Antczak et al., 2010) that act to recruit and activate a variety of immune cells to deal with the invading microorganism. Thus, platelets play a key role in the innate immune system where they directly act to kill bacteria as well as coordinating the response of the immune system to the pathogens.

### 4. The role of platelets in infective endocarditis

IE arises when the bacteria subvert the platelet response to infection and as a result, platelets become part of the pathogenic process. In IE the platelets interact with the bacteria and become activated. They secrete anti-microbial peptides but the bacteria are resistant. Once activated the platelets aggregate resulting in the formation of a platelet-bacteria aggregate. Not only are the bacteria resistant to the anti-bacterial peptides (Bayer et al., 1998; Fowler et al., 2000), they become surrounded by platelets and are able to evade immune surveillance. To further complicate matters even if the bacteria are susceptible to antibiotics, many antibiotics have poor penetration into the thrombus despite adequate plasma levels making treatment more difficult.

While the list of pathogens that have been known to cause IE is long (Baddour et al., 2005), the vast majority of cases with an identified pathogen are due to Staphylococci (primarily *S. aureus*) or Streptococci (primarily *S. sanguinis* and *S. oralis*). However, around 25% of IE cases

are culture negative with no bacteria isolated from the blood (Naber and Erbel, 2007). There are a number of reasons for the failure to culture any organisms such as commencement of antibiotic therapy prior to obtaining the blood sample, infection with a fastidious bacterium or a non-bacterial (e.g., fungal) endocarditis. In this review we will focus on the mechanism of platelet activation by Staphylococci and Streptococci as not only are they the dominant species involved in IE but they are also the best studied. While even different strains of a bacterial species differ in their ability to interact with platelets some general principles can be seen which is important in devising new treatment strategies.

### **5. Platelet-bacterial interactions: General observations**

There are three different types of interaction between platelets and bacteria. The first is an inherent ability of platelet receptors to recognise bacterial surface components. Alternatively, plasma proteins can bind to bacteria and these proteins can in turn bind to a platelet receptor. Typically these are acute phase reactants such as fibrinogen and complement. A third mechanism for interacting with platelets is the secretion of bacterial products or toxins that interact with platelets. The binding of platelets to bacteria either through a direct interaction or via a bridging protein can mediate platelet adhesion and/or platelet activation. Interactions with bacterial toxins leads to either platelet lysis or platelet activation. Typically bacterial proteins that mediate adhesion are distinct from those that mediate aggregation. Thus, bacteria can support platelet adhesion and/or trigger platelet activation. During sepsis the primary interaction between platelets and bacteria is platelet activation and is mediated by both toxin secretion and a direct interaction with the bacteria. However, infective endocarditis is a focal infection of a damaged heart valve. The initial step is mediated by adhesion to the damaged valve as well as subsequent adhesion of platelets to the immobilised bacteria. This adhesive interaction is important in ensuring that the bacteria and thrombus remain attached to the valve despite the presence of turbulent flow conditions. For IE to develop the initial adhesive interaction must be followed by activation of the platelets leading to platelet recruitment and growth of the thrombus. Most bacteria can interact with platelets through multiple mechanisms making it difficult to identify the roles of the different proteins (both bacterial and platelet) and is further complicated by interactions that are not only species-specific but strain-specific as well.

### **6. Platelet-bacterial interactions: The Staphylococcus**

Regardless of the modern advances in antimicrobial therapy and surgical intervention *Staphylococcus aureus* is still the most frequent etiologic microorganism found in Infective endocarditis (Rasmussen et al., 2011). Its interaction with platelets is well characterised. Much of the investigations to date have focused on two separate but related features of this relationship; 1) toxins and 2) cell wall protein mediators of platelet activation (Table 1).

*S. aureus* is known to secrete several extracellular toxins. Alpha ( $\alpha$ )-toxin is a 34 kDa toxin composed of 293 amino acids (Bernheimer, 1965). It is produced by almost all strains of *S. aureus*. Its expression is accessory-gene regulon (agr)-regulated and is secreted into the extracellular environment as a monomeric water soluble protein (Ikigai and Nakae, 1985). The toxin disrupts the cell membranes by binding to the lipid bilayer, forming an oligomeric structure that forms a water filled transmembrane pore (Valeva et al., 1996). Studies have demonstrated that the toxin has primarily two modes of interaction with host

cells. These include binding specifically to the host target at low concentrations and non-specific adsorption to host target cell membranes at higher concentrations (Hildebrand et al., 1991).

Siegel and Cohen were the first to demonstrate that addition of  $\alpha$ -toxin to human platelet-rich plasma induced platelets to undergo shape change and aggregation (Siegel and Cohen, 1964). In this study the authors demonstrated that platelets leaked their intracellular ions  $\text{NAD}^+$ ,  $\text{K}^+$  and ATP but not protein, into the surrounding environment thus concluding that the platelets were not being lysed. Additional studies demonstrated that when platelets were treated with  $\alpha$ -toxin it caused them to swell but there were no clear signs of platelet lysis by electron microscopy (Bernheimer and Schwartz, 1965; Manohar et al., 1967). Further investigations into the molecular mechanism through which platelets became activated, found that pore formation gave rise to an increase in intracellular calcium concentration (Arvand et al., 1990; Baliakina et al., 1999). Arvand et al demonstrated that  $\alpha$ -toxin triggers a platelet signal that leads to secretion of intracellular contents including procoagulant mediators, platelet factor 4 and factor V. Secreted factor V in turn associates with the platelet membrane leading to assembly of the prothrombinase complex (Arvand et al., 1990). This explains the major pathway responsible for the procoagulatory effects of  $\alpha$ -toxin. Bayer et al. used 2 models to investigate the role of  $\alpha$ -toxin on platelets. In the first and consistent with the above observations, the authors demonstrated that  $\alpha$ -toxin caused platelet lysis which in turn caused the release of platelet microbial proteins (PMP's). The release of PMPs from platelets was bactericidal to *S. aureus*. Using an animal model of endocarditis the authors demonstrated that different strains of *S. aureus* differed in the expression of functional versus mutant forms of  $\alpha$ -toxin. Under these conditions, the *S. aureus* strains producing either minimal or no  $\alpha$ -toxin were less virulent in vivo than wild-type strains (Bayer et al., 1997). Wild-type *S. aureus* strains or indeed an isogenic strain engineered to over-express  $\alpha$ -toxin were associated with increased release of PMP from platelets. These results suggest that when *S. aureus* releases  $\alpha$ -toxin in the vicinity of platelets it triggers them to release of PMP's and therefore forging a protective role for the host by destroying the  $\alpha$ -toxin producing *S. aureus*.

Lipoteichoic acid (LTA) is a component of gram positive bacteria (Morath et al., 2005) and is often released from the bacteria upon lysis or after treatment with  $\beta$ -lactam antibiotics (Lotz et al., 2006). It also stimulates a strong immune response through an interaction with toll like receptors expressed on many host cells (Zahringer et al., 2008). Toll like receptor 2 (TLR2) recognises LTA and there are now many reports in the literature demonstrating that TLR2 is expressed and functional on platelets (Blair et al., 2009; Keane et al., 2010b; Kerrigan et al., 2008; Ward et al., 2005) suggesting that platelets can respond to LTA. Early reports demonstrated that *S. aureus* LTA inhibits platelet activation by activating the cyclic AMP pathway (Sheu et al., 2000a; Sheu et al., 2000b).

*S. aureus* predominantly uses multiple cell wall surface proteins to interact with platelets to trigger their activation. Early studies by Hawiger et al. demonstrated that *S. aureus* cell wall protein A acts as a receptor for specific anti-staphylococcal antibodies which in turn bind  $\text{Fc}\gamma\text{RIIIa}$  on platelets (Hawiger et al., 1979). This interaction triggers an intracellular signal that leads to granule release and platelet aggregation. While this interaction is important, deletion of protein A failed to abolish *S. aureus* binding to platelets. This observation suggests that other interactions between *S. aureus* and platelets exist.

Clumping factor A (ClfA) is a 97kDa protein has been shown to bind plasma fibrinogen. A mutant of *S. aureus* lacking clumping factor A (ClfA) failed to adhere to platelets, suggesting that ClfA binds fibrinogen which in turn binds the platelet fibrinogen receptor, GPIIb/IIIa (Sullam et al., 1996). Further characterisation of this interaction suggested that ClfA also requires IgG in order to trigger platelet aggregation. Addition of fibrinogen and ClfA-specific immunoglobulin to the plasma-free system led to *S. aureus*-induced platelet aggregation. Even though resting GPIIb/IIIa has little or no affinity for soluble fibrinogen it can still bind fibrinogen bound to bacteria, however this is not enough to trigger activation. To trigger full platelet activation both fibrinogen and specific immunoglobulin must bind to the A domain on ClfA. There are two distinct sites on ClfA that allows fibrinogen and IgG binding at the same time (Loughman et al., 2005). Once bound fibrinogen molecules can engage resting GPIIb/IIIa, aided by bound ClfA specific immunoglobulin, which encourages the clustering of Fc receptor, FcγRIIIa. This triggers activation of signal transduction leading to conformational change in GPIIb/IIIa and aggregation of platelets.

Deletion of the fibrinogen binding domain (ClfA-PY) but not the IgG binding domain on ClfA led to the discovery of a second pathway *S. aureus* uses to induce platelet aggregation. By removing the fibrinogen binding domain in ClfA *S. aureus* induced platelet aggregation very slowly (between 8-20 minutes compared to 2-4 mins). These results suggest that IgG binding to ClfA alone is not enough to trigger platelet aggregation. Using a series of elimination experiments Loughman et al. demonstrated that complement must assemble on the *S. aureus* surface and then bind to unidentified complement receptors on the platelet. Therefore, in the absence of fibrinogen binding complement and specific immunoglobulin are required for platelet activation to occur (Loughman et al., 2005).

A major limitation in our current understanding of platelet bacterial interactions stems from the fact that the majority of studies cited in the literature to date have been carried out under static conditions (static adhesion assays) or non-physiological stirring conditions (platelet aggregation). Therefore, data obtained using *in vitro* assays may not be relevant to the fluid shear environment that platelets encounter in the vasculature. Indeed many reports suggests that the local fluid environment of the circulation critically affects the molecular pathways of cell-cell interactions (Varki, 1994). All of the early *S. aureus* studies were carried out under static or non-physiological stirring conditions and therefore it is difficult to relate these studies to the disease processes. Studies using a cone and plate viscometer (a device that shears cells at a given flow rate) have demonstrated that protein A, ClfA, SdrC, SdrD and SdrE are important in thrombus formation (George et al., 2007; George et al., 2006; Pawar et al., 2004). However, extremely high shear rates were used in these rheological studies. Using another method of investigating the influence of shear rates on *S. aureus* ability to induce platelet activation, Kerrigan et al. perfused platelets over an immobilised monolayer of *S. aureus* in a parallel flow chamber. This method demonstrated that platelets perfused over *S. aureus* under shear conditions equivalent to arterial pressure led to very strong adhesion followed by rapid aggregate formation (Kerrigan et al., 2008). Deletion of ClfA from *S. aureus*, abolished adhesion and aggregate formation under all shear rates investigated. Using a plasma-free system, fibrinogen led to single platelet adhesion but not aggregate formation. Specific immunoglobulin failed to have any effect on either platelet adhesion or aggregation. However, addition of fibrinogen and specific immunoglobulin to the plasma-free system led to platelet adhesion followed by aggregate formation (Kerrigan et al., 2008) thus highlighting the importance of

fibrinogen and IgG in aggregate formation induced by *S. aureus*. No interaction was seen under low shear conditions using a parallel flow chamber.

*S. aureus* have a wide array of proteins expressed on their surface. This protein expression profile is most likely part of their survival. For example, ClfA is expressed weakly at the exponential phase of growth whereas is expressed strongly at the stationary phase of growth. In contrast to this another major *S. aureus* protein, fibronectin binding protein A (FnBPA) is strongly expressed at the exponential phase of growth and weakly expressed at the stationary phase of growth.

FnBPA is a 112kDa cell wall bound protein which binds plasma fibronectin and immunoglobulin. Fnbp contain a specific immunoglobulin binding domain (A domain) and a separate fibronectin binding domain (BCD). The FnBPA A domain is similar in structure and function to that of the ClfA A domain. FnBPA possesses two different but related mechanisms of engaging and activating platelets (Fitzgerald et al., 2006b). In the first mechanism, fibrinogen can bind to the A domain which crosslinks to GPIIb/IIIa, and specific immunoglobulin must crosslink to Fc $\gamma$ RIIa to trigger platelet activation and aggregation (Fitzgerald et al., 2006b). In the second mechanism the fibronectin binding domain, BCD, can independently activate platelets. Fibronectin can bind to *S. aureus* via the FnBPA BCD domain by the tandem  $\beta$ -zipper mechanism (Meenan et al., 2007; Raibaud et al., 2005; Schwarz et al., 2003) and also to platelet GPIIbIIIa through the common integrin recognition motif RGD (Fitzgerald et al., 2006b). The signal to trigger platelet activation/aggregation is complete when specific immunoglobulin binds the A domain of FnBPA and cross links to platelet Fc $\gamma$ RIIa.

Clumping factor B is a 98 kDa protein highly expressed on the surface of *S. aureus* during the exponential phase of growth and shares sequence homology with ClfA (McAleese et al., 2001). Similar to ClfA, ClfB can also bind fibrinogen and specific immunoglobulin. Deletion of the fibrinogen binding site on ClfB led to a slower aggregation. Characterization of this slower response suggested that complement assembly was required along with immunoglobulin to trigger aggregation (Miajlovic et al., 2007). Therefore similar to *S. aureus* ClfA and FnBPA, ClfB is also capable of triggering platelet aggregation via 2 specific mechanisms; fibrinogen and immunoglobulin or complement and immunoglobulin. Although the complement receptor on platelets has not yet been definitively identified in these interactions, Nguyen et al. has demonstrated that *S. aureus* protein A is capable of binding to the complement receptor gC1qR/p33 (Nguyen et al., 2000). As gC1qR/p33 is only expressed on platelets upon activation rather than at resting, it suggests that the complement interaction may act as an anchor, as it this interaction occurs after the initial platelet activation response.

Staphylococcal protein A (SpA) is a 55kDa protein expressed on greater than 90% of *S. aureus* strains. SpA is made up of 5 repeat domains (A-E) which have been shown to bind to the A1 domain of the major plasma protein vonWillebrand factor with high affinity (low nM range) (Hartleib et al., 2000; O'Seaghdha et al., 2006). Platelets express a high affinity vonWillebrand factor receptor called GPIb $\alpha$  (Andrews et al., 2003). Under very high shear conditions, Pawar and colleagues demonstrated that deletion of SpA from *S. aureus* significantly reduced its interaction with platelets (Pawar et al., 2004). Furthermore, preincubating platelet rich plasma with a vonWillebrand Factor antibody or indeed blocking the platelet GPIb $\alpha$  receptor with an inhibitory monoclonal antibody partially inhibited the

platelet-*S. aureus* interaction (Pawar et al., 2004). Thus highlighting the importance of this platelet specific receptor in recognising *S. aureus*.

Bacteria	Bacterial protein	Platelet receptor	Bridging protein	Response
<i>Staphylococcus aureus</i>	$\alpha$ -toxin	None	None	Aggregation
	Lipoteichoic acid	Not identified	None	Aggregation
	Protein A	Fc $\gamma$ RIIa, gC1R/p33, GPIb $\alpha$	IgG, complement, vonWillebrand factor	Aggregation / adhesion / thrombus formation
	ClfA	GPIIbIIIa, Fc $\gamma$ RIIa,	Fibrinogen, IgG & complement	Aggregation / thrombus formation
	SdrC	Not identified	Not identified	Thrombus formation
	SdrD	Not identified	Not identified	Thrombus formation
	SdrE	Not identified	Not identified	Thrombus formation
	FnbpA/B	GPIIbIIIa, Fc $\gamma$ RIIa	Fibrinogen, IgG & complement	Aggregation / thrombus formation
	ClfB	GPIIbIIIa, Fc $\gamma$ RIIa	Fibrinogen, IgG & complement	
	SraP	Not identified	None	Thrombus formation
	IsdB	GPIIbIIIa	None	Aggregation / adhesion

Table 1. List of molecular interactions between Staphylococci and platelets that contribute to Infective Endocarditis

Serine rich protein SraP is a 227kDa large protein and a member of the highly conserved family of serine rich surface glycoproteins expressed on the cell wall of *S. aureus* (Siboo et al., 2005). A mutant strain of *S. aureus* lacking expression of SraP displayed signs of reduced virulence in a rabbit model of infective endocarditis, implicating its role in the development of a growing thrombus on a cardiac valve. The platelet receptor that SraP binds to is not currently known. SraP shares similarity with a group of cell wall-associated glycoproteins (Ramboarina et al., 2010) found in a number of other organisms including *Streptococcus sanguinis* (Plummer et al., 2005), *Streptococcus gordonii* (Kerrigan et al., 2007) both of which have been shown to bind to platelet GPIb $\alpha$ . Interestingly however, SraP does not seem to bind to GPIb $\alpha$ .



In vivo, *S. aureus* has restricted access to iron and as a result express iron regulated surface proteins to capture haem from haemoglobin and transport it into the cell (Skaar and Schneewind, 2004). Iron-regulated surface determinant B (IsdB) is a 70kDa family member that has been shown to bind to the platelet fibrinogen receptor GPIIb/IIIa. *S. aureus* grown in iron limited conditions bound to platelets in a plasma free environment, suggesting that a plasma bridge bridge is not necessary for interacting with or inducing platelet activation. Mutants defective in the expression of IsdB were unable to adhere to or aggregate platelets. Using surface plasmon resonance Miajlovic et al demonstrated a direct interaction between purified GPIIb/IIIa and recombinant IsdB (Miajlovic et al., 2010).

In addition to *S. aureus* having the ability to interact with platelet either directly or indirectly Youssefian and colleagues reported that platelets were also capable of internalising *S. aureus* (Youssefian et al., 2002). While internalisation corresponded with platelet activation the mechanism through which this occurred is currently not known. Moreover it is also yet to be established whether the *S. aureus* is destroyed once internalised in a manner similar to phagocytosis by immune cells.

## 7. Platelet-bacterial interactions: The Streptococcus

Viridans streptococci are common commensals of the oral cavity, respiratory tract, and gastrointestinal mucosa. In their respective environment these microorganisms are harmless, however following trauma to the mucous membranes they can enter to the normally sterile environment of the bloodstream. Once inside the bloodstream the viridans streptococci act as pathogens (Baddour et al., 1989) and often colonise heart valves, causing infective endocarditis (Moreillon et al., 2002) or become implanted in atherosclerotic plaques, exacerbating atherosclerosis (Chiu, 1999) mainly through an interaction with platelets (Table 2).

*Streptococcus sanguinis* is a common oral microorganism that is isolated from patients with infective endocarditis. In fact early studies demonstrated that 60% of *S. sanguinis* strains induced platelet aggregation in vitro (Herzberg and Meyer, 1996). Douglas et al provided strong evidence that there is a relationship between the virulence of the infecting *S. sanguinis* strains and their ability to aggregate platelets in vitro (Douglas et al., 1990). *S. sanguinis* induced platelet aggregation was largely found to be dependent on physiological concentrations of calcium and fibrinogen, and some strains required non-specific antibody. Platelet adhesion to *S. sanguinis* occurred independently of calcium, fibrinogen or non-specific antibody, suggesting that platelet adhesion and platelet aggregation are mediated independently of each other (Kerrigan et al., 2002). These observations led to the early model of platelet bacterial interaction where a class I component mediated adhesion to the platelet, a class II component mediates a calcium dependent activation of the platelet and finally a class III component mediates a calcium and fibrinogen-dependent amplification of the response (Herzberg, 1996).

The initial studies focused on identifying the class I and class II components. Treatment of *S. sanguinis* with L- (tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK)-trypsin liberated cell free peptides (Herzberg et al., 1983). Purification of these peptides failed to support platelet adhesion or trigger platelet aggregation, however, did inhibit *S. sanguinis* mediated platelet aggregation and adhesion. This studies concluded that that these TPCK-tryptic peptides contained antigenic determinants that recognise platelets thus preventing *S.*

*sanguinis* from binding. Using immunoaffinity chromatography and ion exchange chromatography, Erickson and colleagues identified a platelet aggregation-associated protein (PAAP) (Erickson and Herzberg, 1990). PAAP is synthesized as a 150 kDa glycoprotein which is 40% carbohydrate and is constitutively expressed on the surface of *S. sanguinis* (Erickson and Herzberg, 1993; Erickson et al., 1992). The peptide sequence pro-gly-glu-gln-gly-pro-lys in the PAAP conforms to a predicted consensus motif common to the platelet interactive domain of collagen, lys-pro-gly-glu-pro-gly-pro-lys (Erickson and Herzberg, 1990). More recently Herzberg and colleagues identified a putative collagen-binding protein containing 2 PAAP sequences (Herzberg et al., 2005). PAAP is environmentally controlled during infection in response to high temperature (fever) or exposed collagen (exposed on damaged blood vessels or damaged heart valves) (Heimdahl et al., 1990). Partial sequence alignment shows homology of PAAP to heat shock proteins of *Mycobacterium tuberculosis* and *E. coli* (Herzberg and Meyer, 1996). The platelet receptor for PAAP is currently unidentified.

Ford et al demonstrated that *S. sanguinis* strain NCTC 7863 induced aggregation of normal platelets suspended in plasma however removal of plasma proteins abolished platelet aggregation (Ford et al., 1996). The long lag time (12-15mins) of *S. sanguinis* strain 7863 was progressively shortened by incubating the bacteria in plasma for increasing lengths of time prior to addition to platelets. This suggested that plasma proteins were essential for platelet aggregation. Subsequent experiments demonstrated that complement assembly on the surface of the bacteria was necessary for aggregation of platelets. Further experiments demonstrated that complement assembly was not enough to trigger platelet aggregation which led to the discovery that IgG and fibrinogen was necessary to complete the aggregation process (Ford et al., 1997). More recently McNicol and colleagues demonstrated that depletion of *S. sanguinis*-specific antibodies from plasma prevented platelet aggregation (McNicol et al., 2006). Following *S. sanguinis* binding, addition of antibodies led to rapid phosphorylation of the platelet antibody receptor, FcγRIIIa (Pampolina and McNicol, 2005) and further downstream effector targets such as phospholipase C<sub>2</sub>, syk and adapter molecule LAT.

In 2002 Kerrigan et al, demonstrated that *S. sanguinis* strain 133-79 bound to the platelet vonWillebrand factor receptor, GPIIb<sub>3</sub> (Kerrigan et al., 2002). There was no requirement for vonWillebrand factor or immunoglobulin binding in this system, suggesting that *S. sanguinis* binds directly to platelet GPIIb<sub>3</sub>. Confirmation for the role of GPIIb<sub>3</sub> was provided when a range of site-specific inhibitory monoclonal antibodies against GPIIb<sub>3</sub> prevented *S. sanguinis* binding to the platelet. In addition, enzymatic cleavage of GPIIb<sub>3</sub> using the snake venom from a viper pit localised the binding region within the N-terminal 1-225 portion of GPIIb<sub>3</sub>. Finally, platelets from patients with Bernard Soulier Syndrome (patients who fail to express GPIIb<sub>3</sub> on the surface of their platelets) did not aggregate in response to *S. sanguinis* (Kerrigan et al., 2002). The *S. sanguinis* protein that binds GPIIb<sub>3</sub> was purified from cell wall extracts by chromatography on GPIIb<sub>3</sub> and wheat germ agglutinin affinity matrices (Plummer et al., 2005). This led to the identification of a highly glycosylated serine-rich protein called serine-rich protein A (SrpA). An insertional inactivation mutant lacking the SrpA of *S. sanguinis* showed a significant increase in the lag time to aggregation, implicating this protein in platelet aggregation. In addition, platelet adhesion to the SrpA mutant was significantly reduced, however not abolished, suggesting other factors are involved in supporting platelet adhesion.

*Streptococcus gordonii* is a close but distinct relative of *S. sanguinis* (Nobbs et al., 2009), however initial reports suggested that *S. gordonii* could not induce platelet aggregation (Douglas et al., 1990). More in depth characterisation has demonstrated that *S. gordonii* is capable of supporting platelet adhesion and inducing platelets aggregation in a strain dependent manner. Glycosylated surface protein B is a large 280kDa protein expressed on the surface of *S. gordonii* strain M99. It is heavily glycosylated with glucose and glucosamine and is transported to the cell surface via an accessory system comprising of the SecA2 and the SecY2 proteins (Bensing and Sullam, 2002; Takahashi et al., 2004). GspB has been shown to be highly homologous to an expanding family of Gram-positive bacterial cell surface proteins that includes *S. aureus* serine rich protein SraP (Siboo et al., 2005) *S. sanguis* serine-rich protein SrpA (Plummer et al., 2005), *S. gordonii* DL1 sialic acid-binding protein Hsa (Takahashi et al., 2002) and the *S. parasanguinis* fimbriae-associated protein Fap1 (Wu et al., 2007). These proteins were originally discovered because of their ability to bind a variety of sialylated glycoproteins. Platelet GPIb $\alpha$  is an example of a sialylated glycoprotein and as a result has been shown to bind *S. gordonii* GspB and Hsa (Bensing et al., 2004). Additional molecular glycan characterisation demonstrated that GspB specifically binds O-linked sialic acid residues on GPIb $\alpha$  (Takamatsu et al., 2005), whereas Hsa specifically binds N-linked sialic acid residues on GPIb $\alpha$  and GPIIb/IIIa (Yajima et al., 2005). Interestingly an isogenic mutant lacking the expression of Hsa in *S. gordonii* strain DL1 failed to affect percent platelet aggregation however reduced platelet adhesion by  $\sim 50\%$ . These more recent functional studies suggest that additional protein interactions are necessary for supporting platelet adhesion (Jakubovics et al., 2005a).

*S. gordonii* expresses a large protein of  $\sim 3500$  amino acids with a high molecular weight of 397 kDa designated platelet adherence protein A (PadA) (Petersen et al., 2010). PadA contains a short stretch of amino acid residues which displays weak homology to A1 and C1 domain of the plasma protein, vonWillebrand factor (vWf). These domains in vWf are essential for interactions with platelet GPIb and GPIIb/IIIa, respectively. Disruption of the PadA gene from *S. gordonii* DL1 failed to affect binding to glyocalacin (soluble purified GPIb $\alpha$ ), however, ablated binding to purified GPIIb/IIIa. Furthermore, platelet adhesion to *S. gordonii* DL1 was significantly reduced by preincubation of platelets with an integrin recognition RGD-containing peptide or the GPIIb/IIIa inhibitor, abciximab (Petersen et al., 2010). Earlier studies demonstrated that *S. gordonii* DL1 bound specifically to GPIIb but not GPIIIa of the GPIIb/IIIa complex (Yajima et al., 2005). Collectively these results suggest that platelet adhesion is a multifactorial event where Hsa binds GPIb $\alpha$  and PadA binds GPIIb/IIIa and together they act synergistically to support platelet adhesion.

Platelets are very sensitive to shear and some platelet-substrate interactions only manifest themselves upon exposure to shear. For example, under low shear conditions there is no interaction between platelets and vWf however under high shear conditions platelets roll along the vWf coated surface (Ruggeri, 2009). Perfusing platelets over immobilised *S. sanguinis* or *S. gordonii* in a parallel flow chamber under low shear (venous shear), platelets interacted with a typical rolling behaviour followed by firm adhesion (Jakubovics et al., 2005a; Plummer et al., 2005). This phenomena is highly characteristic of platelet rolling on damaged endothelium (Ruggeri, 2009). Rolling is mediated by platelet GPIb $\alpha$  where is the fast on-off rate of the receptor allows loss of interaction between GPIb $\alpha$  and the bacteria on one side of the platelet leading to the formation of another GPIb $\alpha$ -bacterial interaction on

the other side of the platelet. Deletion of the *S. sanguinis* GPIb $\alpha$ -binding protein SrpA or indeed the *S. gordonii* GPIb $\alpha$ -binding protein Hsa abolished the rolling behaviour, suggesting that these proteins form the initial attachment of platelets with the bacteria under physiological shear conditions. Soluble vWf exists in the plasma in a conformation that is not recognisable by platelet GPIb $\alpha$ . However at the site of injury, vWf binds to extracellular matrix proteins forming a thrombotic surface for the platelet. Typically platelets roll along immobilised vWf under high shear conditions. The high shear induces a conformational change in vWf making it recognisable to GPIb $\alpha$ . As *S. gordonii* Hsa and *S. sanguinis* SrpA can support static platelet adhesion, or indeed mediate rolling of platelets under low shear conditions it suggests that Hsa and SrpA exist in a unique conformation that is recognisable by GPIb $\alpha$ , as their receptor conformation is not believed to be altered when subjected to shear. The process of rolling is to slow the platelet down from the high shear force experienced in the vasculature long enough to allow it firmly adhere to the bacteria. Firm adhesion is complete when platelet GPIIb/IIIa interacts with *S. gordonii* PadA.

Once the platelets become firmly adhered to *S. gordonii* by engaging with either GPIb $\alpha$  or GPIIbIIIa, a signal is generated in the platelet that results in the platelet changing shape and spreading out on the bacterial surface. The function of platelet spreading is essential for the platelet to withstand the shear forces experienced in the vasculature. Platelet spreading is a particularly important in the development of thrombotic vegetations in infective endocarditis because the lesions around the lesion on the cardiac valve are often very turbulent. Therefore, platelets require the conversion from a discoid shape to a fully spread cell to withstand turbulent shear force. Keane et al, demonstrated that engagement of either GPIb $\alpha$  or GPIIbIIIa, the ITAM-bearing receptor, Fc $\gamma$ RIIa and its downstream effectors syk and phospholipase C $\gamma$ 2 became tyrosine phosphorylated which suggests that this pathway is essential for platelet spreading (Keane et al., 2010a). In addition tyrosine phosphorylation of the Fc $\gamma$ RIIa resulted in platelet degranulation, a step critical for inducing and amplifying platelet aggregation.

Once platelets become firmly adhered and a signal is generated in the platelet it leads to platelet aggregation. Interestingly, while a mutant *S. gordonii* strain lacking expression of Hsa displayed reduced ability to support platelet adhesion, platelet aggregation remained unaffected. This observation suggests that different proteins expressed on the surface of *S. gordonii* mediate different interactions and subsequent responses in platelets. To address this Kerrigan et al used a proteomic approach to identify differentially expressed proteins on a strain of *S. gordonii* that induces platelet aggregation (*S. gordonii* strain DL1) versus one that does not (*S. gordonii* strain Blackburn). Cell wall proteins from both strains were removed from the cell wall using lysozyme. Recovered proteins were separated by poly-acrylamide gel electrophoresis and 2 bands corresponding to 172 kDa and 164 kDa were shown to be differentially expressed. Mass spectrometry identified these proteins as antigen I/II (Kerrigan et al., 2007). The antigen I/II family of proteins are probably the best characterised proteins on the surface of *S. gordonii*. Originally identified on *Streptococcus mutans*, antigen I/II have now been identified on almost all oral streptococci (Nobbs et al., 2007). In *S. gordonii*, antigen I/II have been designated SspA/B. These proteins are oligospecific adhesins which have been shown to bind to several ligands such as collagen type I (Hedde et al., 2003),  $\beta_1$  integrins (Nobbs et al., 2007), salivary agglutinin glycoprotein (Prakobphol et al., 2000) as well as other bacteria including *P. gingivalis*, *Candida albicans* and *Actinomyces*

*naeslundii* (Demuth et al., 2001; Eglund et al., 2001; Jakubovics et al., 2005b). Deletion of SspA/B from *S. gordonii* DL1 failed to affect either platelet aggregation or platelet adhesion. However, deletion of SspA/B and Hsa together abolished platelet aggregation and reduced platelet adhesion by 50%, similar to the Hsa mutant alone (Kerrigan et al., 2007). Consistent with this over expression of SspA and SspB in the non-platelet reactive surrogate host *Lactococcus lactis* induced platelet aggregation but failed to support platelet adhesion. These results suggest that SspA/B and Hsa must act synergistically when binding to platelets to trigger aggregation and that they are not involved in supporting platelet adhesion. At present the receptor through which SspA/B binds to on the platelets is not current known.

Bacteria	Bacterial protein	Platelet receptor	Bridging protein	Response
<i>S. sanguinis</i>	PAAP	Not identified	None	Aggregation
	Not identified	FcγRIIa	Antibody, fibrinogen & complement	Aggregation
	SrpA	GPIbα	None	Adhesion / aggregation
<i>S. gordonii</i>	GspB	GPIbα	None	Adhesion
	Hsa	GPIbα	None	Adhesion / aggregation
	PadA	GPIIb/IIIa	None	Adhesion
	SspA/B	Not identified	None	Adhesion / Aggregation
<i>S. mitis</i>	PblA/B	Not identified	None	Aggregation
	Lysin	GPIIb/IIIa	fibrinogen	Aggregation
<i>S. mutans</i>	Rgp	Not identified	IgG	Aggregation
	PAc	Not identified	None	Aggregation
<i>S. oralis</i>	Not identified	Not identified	None	Adhesion / aggregation
<i>S. parasanguinis</i>	FimA	Not identified	None	?
	Fap1	Not identified	None	Adhesion
<i>S. pneumoniae</i>	Not identified	TLR2	None	Aggregation

Table 2. List of molecular interactions between Streptococci and platelets that contribute to Infective Endocarditis

*Streptococcus mitis* has also been shown to interact with platelets although reports are conflicting. In 1990, Douglas et al, used several strains of *S. mitis* and found that none of these interacted with platelets. Ohkuni and colleagues suggested that *S. mitis* strain Nm-65

released a 66 kDa protein (*S.mitis*-derived human platelet aggregation factor, Sm-PAF) that induced platelet aggregation (Ohkuni et al., 1997). Characterisation of this secreted protein revealed that it was a toxin that lysed platelets rather than induced platelet aggregation. More recent work by Bensing et al, identified two distinct genetic loci of *S. mitis* strain SF100 that contributes to platelet binding (Bensing et al., 2001a). The first locus encodes PblT. The mechanism through which it binds to platelets has not yet been explored. The second locus encodes two cell wall associated proteins; PblA is a 107 kDa protein and PblB which is a 121 kDa protein (Bensing et al., 2001b). These proteins are unique as neither of the proteins expresses homology to any other bacterial adhesins described, however share similarities with structural components of bacteriophages (Mitchell et al., 2007). Bacteria often bind to oligosaccharides on host cells. For example *S. gordonii* GspB binds to  $\alpha$ 2-3-linked sialic acids on platelets and salivary mucins. Platelets treated with sialidases having different linkage specificities demonstrated that removal of  $\alpha$ 2-8-linked sialic acids resulted in a reduction in *S. mitis* SF100 binding. Gangliosides are glycosphingolipids rich in sialic acids and are found in abundance in lipid rafts in platelets (Marcus et al., 1972). *S. mitis* strains lacking the expression of PblA and PblB demonstrated significant decrease in platelet binding invitro as well as marked reduction in virulence in an animal model of infective endocarditis (Bensing et al., 2001b; Mitchell et al., 2007). More recent studies have demonstrated that *S. mitis* surface bound lysin can bind both free and platelet bound fibrinogen, through its interaction with the Aa and Bb chains of fibrinogen (Seo et al., 2010). Once *S. mitis* has bound fibrinogen this in turn can bind to the platelet fibrinogen receptor, GPIIb/IIIa, initiating thrombus formation.

Although early reports suggest *Streptococcus oralis* is capable of inducing platelet aggregation and supporting platelet adhesion the exact mechanism through which either of these occur is currently unknown.

*Streptococcus mutans* strain Xc induces platelet aggregation by releasing extracts containing serotype-specific polysaccharides which are composed of rhamnose-glucose polymers. An isogenic mutant lacking synthesis the rhamnose-glucose polymers significantly reduced platelet aggregation (Chia et al., 2004). *S. mutants* failed to induce platelet aggregation in the absence of plasma proteins suggesting that a plasma protein possibly bridges the bacteria to the platelet. Subsequent studies identified that addition of serotype-specific IgG to plasma free platelets restored aggregation. The ability of rhamnose polymers to induce platelet aggregation has been known for some time. For example, ristocetin is obtained from *Amycolatopsis lurida* and is well characterised for its ability to induce platelet agglutination. The mechanism of ristocetin induced agglutination of platelets involves vWf binding to platelet GPIIb/IIIa. Cleavage of the rhamnose tetrasaccharide of ristocetin abolished its ability to induce platelet aggregation (Bardsley et al., 1998). Moreover, *S. sanguinis* expresses a platelet associated aggregating protein (PAAP) which is another rhamnose polymer which is thought to be involved in inducing platelet aggregation. Together these results suggest that rhamnose plays an important role in inducing platelet aggregation. Additional studies by Munro et al, demonstrated that an isogenic mutant of *S. mutans* strain V403 lacking the exopolysaccharides glucan and fructan had decreased infectivity in the rat model of endocarditis compared to the wild-type strain (Munro and Macrina, 1993). Protein antigen C (PAC) is a high molecular weight protein expressed by *S. mutans* that has been shown to interact with an unidentified platelet protein (Matsumoto-Nakano et al., 2009). Clinical strains that do not naturally express PAC failed to induce platelet aggregation.

Although the platelet receptor that recognises PAc was not identified, the authors demonstrated that increasing amounts of anti-PAc serum significantly reduced platelet aggregation, suggesting that antibody recognition may be a critical factor.

*Streptococcus parasanguinis* expresses a 36kDa surface protein called FimA. A mutant defective on the expression of FimA from *S. parasanguinis* strain FW213 failed to have any effect on supporting platelet adhesion or inducing platelet aggregation however significantly reduced the extent of endocarditis in the rat model (Burnette-Curley et al., 1995). Based on these observations the exact mechanism by which FimA functions as a virulence factor of endocarditis has yet to be determined, however it is possible that FimA plays a role in adherence to fibrin deposits associated with damaged heart valves. Fimbrae-associated protein 1 (Fap1) is a highly glycosylated serine-rich glycoprotein which shares sequence and structural homology with SrpA of *S. sanguinis*, GspB of *S. gordonii* and SraP of *S. aureus*. SrpA of *S. sanguinis* and GspB of *S. gordonii* have both been shown to interact directly with platelet GPIb $\alpha$  to trigger platelet activation (Wu et al., 2007). To date no studies have demonstrated that Fap1 interacts with GPIb $\alpha$  or indeed with platelets directly.

Early studies by Johnson et al, demonstrated that at low concentrations *Streptococcus pneumoniae* pneumolysin had little effect on platelets, however at higher concentrations platelets were lysed presumably by binding to the sterols present in the platelet plasma membrane and forming multimeric transmembrane pores (Johnson et al., 1981). The ability to form these pores may result in lysis of platelets. Lysis occurred in a time-dependent manner where greater than 50% of platelets were lysed. A more recent study demonstrated that a concentrated sample of supernatant from an overnight growth of *S. pneumoniae* that contained pneumolysin failed to induce human platelet aggregation, moreover a pneumolysin-negative strain of *S. pneumoniae* also induced platelet aggregation suggesting that pneumolysin is not involved in inducing platelet aggregation (Keane et al., 2010b). In this report the authors demonstrated that *S. pneumoniae* binds to platelet toll like receptor 2 (TLR2), a pattern recognition receptor which triggered the PI3kinase/RAP1 pathway which leads to activation of the fibrinogen receptor GPIIb/IIIa.

## 8. Platelet-bacterial interactions: Non staphylococcal, non streptococcal

There is no doubt Staphylococcus and Streptococcus species make up the majority of cases of infective endocarditis, however other opportunistic pathogens, while rare, may also play a role (Table 3). For example recent work by Shannon et al. demonstrated that clinical isolates of *Enterococcus faecalis* induced platelet aggregation. The ability of the *E. faecalis* to induce platelet aggregation was dependent on IgG (Rasmussen et al., 2010). *Helicobacter pylori* has also been shown to interact with platelets. When in plasma it binds vonWillebrand factor, which in turn enables it to interact with GPIb $\alpha$  and trigger platelet aggregation. This is a unique interaction as soluble vonWillebrand factor cannot interact with platelet GPIb $\alpha$ . The *H. pylori* protein that binds vonWillebrand factor is currently not identified (Byrne et al., 2003; Corcoran et al., 2007). *Porphyromonas ginigvalis* secretes a protease called gingipains that acts directly on platelet protease activated receptors (Lourbakos et al., 2001). Naito and colleagues also demonstrated that *P. ginigvalis* expresses a protein called Hgp44 which also induces platelet aggregation. Although the platelet receptor has not been definitively identified antibodies against GPIb $\alpha$  abolish the interaction (Naito et al., 2006). Finally, *Escherichia coli* secretes shiga-like toxin which binds

to the glycosphingolipid receptors on the surface of the platelet and triggers platelet activation (Cooling et al., 1998), however other groups failed to see the interaction in vivo (Viisoreanu et al., 2000). One explanation for these contradictory results is that in vivo the actions of Shiga toxins are complex and many of its actions on platelets are indirect being mediated through effects on other cells such as monocytes (Guessous et al., 2005) and endothelial cells (Motto et al., 2005).

Bacteria	Bacterial protein	Platelet receptor	Bridging protein	Response
<i>Enterococcus faecalis</i>	Not identified	FcγRIIIa	IgG	Aggregation
<i>Helicobacter pylori</i>	Not identified	GPIbα	vonWillebrand Factor	Aggregation
<i>Porphyromonas gingivalis</i>	RgpA/B	PAR1 & PAR4	None	Aggregation
	Hgp44	GPIbα	Not identified	Aggregation
<i>Escherichia coli</i>	Shiga-like toxin	Sphingolipids	None	Aggregation

Table 3. List of molecular interactions between non staphylococcal non streptococcal microorganisms and platelets that may contribute to Infective Endocarditis

## 9. Current and novel treatment options for infective endocarditis

As infective endocarditis is primarily a bacteria infection, often associated with dental and other medical procedures, prophylactic antibiotic treatment was considered to be normal practice. However, more recently the American Heart Association (AHA) and American College of Cardiology (ACC) released a guidance document on infective endocarditis that significantly changed routine practice (Nishimura et al., 2008). In particular they no longer recommend the prophylactic use of antibiotics for dental or other procedures except for a small group of high-risk patients. This was primarily due to the fact that the risks associated with prophylaxis outweigh the benefits. The review panel felt that the biggest risk for IE is not dental or other procedures but rather bleeding from gums due to poor oral hygiene. Thus, so few cases of IE will be prevented by antibiotic prophylaxis during medical procedures but there will be an increase in antibiotic resistance that there is little benefit to prophylaxis. They felt that improved oral hygiene would be more effective at preventing the occurrence of IE. The exception was for very high-risk patients, which are basically patients with prosthetic valves or those with a history of IE.

With the increase in antibiotic-resistant strains of pathogenic bacteria researchers have been looking at new strategies to target bacteria. One such approach is to target the host response to the pathogen (Clatworthy et al., 2007). IE is very amenable to this strategy as it basically arises from an ineffective host response to the infection. If the platelet aggregation response can be prevented there would be no thrombus formation.



The obvious strategy would be to use an anti-platelet agent to prevent the thrombus formation. Aspirin is the most widely used anti-platelet agent and acts to inhibit cyclooxygenase but may not be effective in preventing IE (Chan et al., 2003). While aspirin effectively inhibits COX some bacteria can activate platelets in a COX-independent manner. As it is not known prior to the procedure which bacteria are likely to be involved aspirin would not be sufficient. A more effective strategy would be to use a P2Y<sub>12</sub> antagonist such as clopidogrel. However, its very effectiveness makes it unlikely to be used. The inhibition of platelet function by clopidogrel and other anti-platelet agents cause bleeding and it is unlikely that dentists would be happy to perform extractions and other such procedures when the patient is likely to experience very heavy bleeding. Certainly surgeons will not operate on a patient on clopidogrel and they typically require a reversal of the inhibition before they will consider surgery.

Targeting the bacteria is an approach that is attractive, as it would not interfere with platelet function. However, as we have seen choosing a target is difficult as every species of bacteria interact differently with platelets and even different strains of the same species can interact differently (Fitzgerald et al., 2006a). There is also the problem that bacteria such as *S. aureus* have multiple interactions with platelets and it is not clear which one if any is the critical one during IE. Certainly if it was possible to identify a single bacterial protein that was conserved across many pathogenic strains and was found to be critical in the interaction with platelets it would be possible to produce a vaccine against it (Broughan et al., 2011).

Despite the limitations associated with the use of anti-platelet agents platelets are still a promising target for any potential new drug. This is because so far there are only a few platelet receptors implicated in the response to bacteria primarily GPIIb/IIIa and GPIb $\alpha$ . GPIIb/IIIa plays an important role in *S. aureus*- and *S. gordonii* mediated platelet aggregation but as the fibrinogen receptor it also plays a critical role in platelet aggregation. Because of this important role in platelet function a number of inhibitors of this receptor have been developed. Although only for intravenous use these drugs have been very effective anti-platelet agents (Curtin, 2004). However, they are very potent in their inhibition and will cause a profound inhibition of platelet function along with a prolongation of bleeding time that will not be suitable for prophylaxis during procedures such as dental manipulations.

A second platelet receptor that is important in the platelet response to bacteria is GPIb $\alpha$ , which is the von Willebrand factor receptor. GPIb $\alpha$  is very important in platelet adhesion under shear stress and is a very attractive target in cardiovascular disease. However, despite the efforts of many researchers to discover GPIb $\alpha$  inhibitors none have yet made it to the market (Vanhoorelbeke et al., 2007).

Fc $\gamma$ RIIa has been shown to mediate platelet activation by many different bacteria including Staphylococci and Streptococci. It typically acts in conjunction with GPIb $\alpha$ , GPIIb/IIIa or the complement receptor. Unlike receptors such as GPIb $\alpha$  and GPIIb/IIIa Fc $\gamma$ RIIa is not involved in thrombosis as its role are primarily involved in the immune function of platelets. Thus, antagonists of Fc $\gamma$ RIIa will have little impact on platelet function and will not cause bleeding problems making it an ideal target for prophylactic therapy for IE.

The interaction between platelets and bacteria is the key element of infective endocarditis. While there are many different bacterial proteins that can bind to platelets there are only a few potential receptors on the platelet for these proteins. This makes the platelet a good

target for novel strategies to inhibit this interaction. While there is always a risk of causing bleeding problems with anti-platelet agents Fc $\gamma$ RIIa has been found to be the critical receptor on platelets for the interaction with bacteria. As this receptor is associated with the innate immune functions of platelets rather than with its role in thrombosis targeting Fc $\gamma$ RIIa will have minimal effects on the role of platelets in thrombosis. This strategy would be in line with the recent guidance document on infective endocarditis from AHA/ACC. Prophylactic use of an Fc $\gamma$ RIIa antagonist during medical procedures with no risk of developing resistance. Antibiotic therapy could then be reserved for cases of sepsis or confirmed infective endocarditis.

## 10. References

- Andrews, R.K., E.E. Gardiner, Y. Shen, J.C. Whisstock, and M.C. Berndt. 2003. Glycoprotein Ib-IX-V. *Int J Biochem Cell Biol* 35:1170-1174.
- Antczak, A.J., N. Singh, S.R. Gay, and R.G. Worth. 2010. IgG-complex stimulated platelets: A source of sCD40L and RANTES in initiation of inflammatory cascade. *Cellular Immunology* 263:129-133.
- Arvand, M., S. Bhakdi, B. Dahlback, and K.T. Preissner. 1990. Staphylococcus aureus alpha-toxin attack on human platelets promotes assembly of the prothrombinase complex. *J Biol Chem* 265:14377-14381.
- Asopa, S., A. Patel, O.A. Khan, R. Sharma, and S.K. Ohri. 2007. Non-bacterial thrombotic endocarditis. *Eur J Cardiothorac Surg* 32:696-701.
- Baddour, L.M., G.D. Christensen, J.H. Lowrance, and W.A. Simpson. 1989. Pathogenesis of experimental endocarditis. *Rev Infect Dis* 11:452-463.
- Baddour, L.M., W.R. Wilson, A.S. Bayer, V.G. Fowler, Jr., A.F. Bolger, M.E. Levison, P. Ferrieri, M.A. Gerber, L.Y. Tani, M.H. Gewitz, D.C. Tong, J.M. Steckelberg, R.S. Baltimore, S.T. Shulman, J.C. Burns, D.A. Falace, J.W. Newburger, T.J. Pallasch, M. Takahashi, and K.A. Taubert. 2005. Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America. *Circulation* 111:e394-434.
- Baliakina, E.V., E.V. Gerasimovskaia, A. Romanov Iu, and E. Atakhanov Sh. 1999. [Role of staphylococcus aureus hemolytic toxin-alpha in pathogenesis of infectious endocarditis: studies in vitro]. *Ter Arkh* 71:28-31.
- Bardsley, B., D.H. Williams, and T.P. Baglin. 1998. Cleavage of rhamnose from ristocetin A removes its ability to induce platelet aggregation. *Blood Coagul Fibrinolysis* 9:241-244.
- Bayer, A.S., D. Cheng, M.R. Yeaman, G.R. Corey, R.S. McClelland, L.J. Harrel, and V.G. Fowler, Jr. 1998. In vitro resistance to thrombin-induced platelet microbicidal protein among clinical bacteremic isolates of Staphylococcus aureus correlates with an endovascular infectious source. *Antimicrob Agents Chemother* 42:3169-3172.
- Bayer, A.S., M.D. Ramos, B.E. Menzies, M.R. Yeaman, A.J. Shen, and A.L. Cheung. 1997. Hyperproduction of alpha-toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins. *Infect Immun* 65:4652-4660.

- Bensing, B.A., J.A. Lopez, and P.M. Sullam. 2004. The *Streptococcus gordonii* surface proteins GspB and Hsa mediate binding to sialylated carbohydrate epitopes on the platelet membrane glycoprotein Ibalpha. *Infect Immun* 72:6528-6537.
- Bensing, B.A., C.E. Rubens, and P.M. Sullam. 2001a. Genetic loci of *Streptococcus mitis* that mediate binding to human platelets. *Infect Immun* 69:1373-1380.
- Bensing, B.A., I.R. Siboo, and P.M. Sullam. 2001b. Proteins PblA and PblB of *Streptococcus mitis*, which promote binding to human platelets, are encoded within a lysogenic bacteriophage. *Infect Immun* 69:6186-6192.
- Bensing, B.A., and P.M. Sullam. 2002. An accessory sec locus of *Streptococcus gordonii* is required for export of the surface protein GspB and for normal levels of binding to human platelets. *Mol Microbiol* 44:1081-1094.
- Bernheimer, A.W. 1965. Staphylococcal alpha toxin. *Ann N Y Acad Sci* 128:112-123.
- Bernheimer, A.W., and L.L. Schwartz. 1965. Effect of Staphylococcal and Other Bacterial Toxins on Platelets in Vitro. *J Pathol Bacteriol* 89:209-223.
- Beynon, R.P., V.K. Bahl, and B.D. Prendergast. 2006. Infective endocarditis. *Br Med J* 333:334-339.
- Blair, P., S. Rex, O. Vitseva, L. Beaulieu, K. Tanriverdi, S. Chakrabarti, C. Hayashi, C.A. Genco, M. Iafrati, and J.E. Freedman. 2009. Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. *Circ Res* 104:346-354.
- Broughan, J., R. Anderson, and A.S. Anderson. 2011. Strategies for and advances in the development of *Staphylococcus aureus* prophylactic vaccines. *Expert Review of Vaccines* 10:695-708.
- Burnette-Curley, D., V. Wells, H. Viscount, C.L. Munro, J.C. Fenno, P. Fives-Taylor, and F.L. Macrina. 1995. FimA, a major virulence factor associated with *Streptococcus parasanguis* endocarditis. *Infect Immun* 63:4669-4674.
- Byrne, M.F., S.W. Kerrigan, P.A. Corcoran, J.C. Atherton, F.E. Murray, D.J. Fitzgerald, and D.M. Cox. 2003. *Helicobacter pylori* binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. *Gastroenterology* 124:1846-1854.
- Chan, K., J. Dumesnil, B. Cujec, A. Sanfilippo, J. Jue, M. Turek, T. Robinson, D. Moher, and I.o.t.M.A.S.i.I. Endocarditis. 2003. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. *J Am Coll Cardiol* 42:775-780.
- Chia, J.S., Y.L. Lin, H.T. Lien, and J.Y. Chen. 2004. Platelet aggregation induced by serotype polysaccharides from *Streptococcus mutans*. *Infect Immun* 72:2605-2617.
- Chiu, B. 1999. Multiple infections in carotid atherosclerotic plaques. *Am Heart J* 138:S534-536.
- Clatworthy, A.E., E. Pierson, and D.T. Hung. 2007. Targeting virulence: a new paradigm for antimicrobial therapy. *Nat Chem Biol* 3:541-548.
- Cooling, L.L., K.E. Walker, T. Gille, and T.A. Koerner. 1998. Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid. *Infect Immun* 66:4355-4366.
- Corcoran, P.A., J.C. Atherton, S.W. Kerrigan, T. Wadstrom, F.E. Murray, R.M. Peek, D.J. Fitzgerald, D.M. Cox, and M.F. Byrne. 2007. The effect of different strains of *Helicobacter pylori* on platelet aggregation. *Can J Gastroenterol* 21:367-370.
- Cox, D., S.W. Kerrigan, and S.P. Watson. 2011. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. *Journal of Thrombosis and Haemostasis* 9:1097-1107.
- Curtin, R. 2004. Intravenous glycoprotein IIb/IIIa antagonists: their benefits, problems and future developments. *Curr Pharm Des* 10:1577-1585.

- Demuth, D.R., D.C. Irvine, J.W. Costerton, G.S. Cook, and R.J. Lamont. 2001. Discrete protein determinant directs the species-specific adherence of *Porphyromonas gingivalis* to oral streptococci. *Infect Immun* 69:5736-5741.
- Douglas, C.W., P.R. Brown, and F.E. Preston. 1990. Platelet aggregation by oral streptococci. *FEMS Microbiol Lett* 60:63-67.
- Egland, P.G., L.D. Du, and P.E. Kolenbrander. 2001. Identification of independent *Streptococcus gordonii* SspA and SspB functions in coaggregation with *Actinomyces naeslundii*. *Infect Immun* 69:7512-7516.
- Erickson, P.R., and M.C. Herzberg. 1990. Purification and partial characterization of a 65-kDa platelet aggregation-associated protein antigen from the surface of *Streptococcus sanguis*. *J Biol Chem* 265:14080-14087.
- Erickson, P.R., and M.C. Herzberg. 1993. The *Streptococcus sanguis* platelet aggregation-associated protein. Identification and characterization of the minimal platelet-interactive domain. *J Biol Chem* 268:1646-1649.
- Erickson, P.R., M.C. Herzberg, and G. Tierney. 1992. Cross-reactive immunodeterminants on *Streptococcus sanguis* and collagen. Predicting a structural motif of platelet-interactive domains. *J Biol Chem* 267:10018-10023.
- Fitzgerald, J.R., T.J. Foster, and D. Cox. 2006a. The interaction of bacterial pathogens with platelets. *Nat Rev Microbiol* 4:445-457.
- Fitzgerald, J.R., A. Loughman, F. Keane, M. Brennan, M. Knobel, J. Higgins, L. Visai, P. Speziale, D. Cox, and T.J. Foster. 2006b. Fibronectin-binding proteins of *Staphylococcus aureus* mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcγRIIIa receptor. *Mol Microbiol* 59:212-230.
- Ford, I., C.W. Douglas, D. Cox, D.G. Rees, J. Heath, and F.E. Preston. 1997. The role of immunoglobulin G and fibrinogen in platelet aggregation by *Streptococcus sanguis*. *Br J Haematol* 97:737-746.
- Ford, I., C.W. Douglas, J. Heath, C. Rees, and F.E. Preston. 1996. Evidence for the involvement of complement proteins in platelet aggregation by *Streptococcus sanguis* NCTC 7863. *Br J Haematol* 94:729-739.
- Fowler, V.G., Jr., L.M. McIntyre, M.R. Yeaman, G.E. Peterson, L. Barth Reller, G.R. Corey, D. Wray, and A.S. Bayer. 2000. In vitro resistance to thrombin-induced platelet microbicidal protein in isolates of *Staphylococcus aureus* from endocarditis patients correlates with an intravascular device source. *J Infect Dis* 182:1251-1254.
- George, N.P., K. Konstantopoulos, and J.M. Ross. 2007. Differential kinetics and molecular recognition mechanisms involved in early versus late growth phase *Staphylococcus aureus* cell binding to platelet layers under physiological shear conditions. *J Infect Dis* 196:639-646.
- George, N.P., Q. Wei, P.K. Shin, K. Konstantopoulos, and J.M. Ross. 2006. *Staphylococcus aureus* adhesion via Spa, ClfA, and SdrCDE to immobilized platelets demonstrates shear-dependent behavior. *Arterioscler Thromb Vasc Biol* 26:2394-2400.
- Guessous, F., M. Marcinkiewicz, R. Polanowska-Grabowska, T.R. Keepers, T. Obrig, and A.R. Gear. 2005. Shiga toxin 2 and lipopolysaccharide cause monocytic THP-1 cells to release factors which activate platelet function. *Thromb Haemost* 94:1019-1027.
- Hartleib, J., N. Kohler, R.B. Dickinson, G.S. Chhatwal, J.J. Sixma, O.M. Hartford, T.J. Foster, G. Peters, B.E. Kehrel, and M. Herrmann. 2000. Protein A is the von Willebrand factor binding protein on *Staphylococcus aureus*. *Blood* 96:2149-2156.

- Hawiger, J., S. Steckley, D. Hammond, C. Cheng, S. Timmons, A.D. Glick, and R.M. Des Prez. 1979. Staphylococci-induced human platelet injury mediated by protein A and immunoglobulin G Fc fragment receptor. *J Clin Invest* 64:931-937.
- Heddle, C., A.H. Nobbs, N.S. Jakubovics, M. Gal, J.P. Mansell, D. Dymock, and H.F. Jenkinson. 2003. Host collagen signal induces antigen I/II adhesin and invasin gene expression in oral *Streptococcus gordonii*. *Mol Microbiol* 50:597-607.
- Heimdahl, A., G. Hall, M. Hedberg, H. Sandberg, P.O. Soder, K. Tuner, and C.E. Nord. 1990. Detection and quantitation by lysis-filtration of bacteremia after different oral surgical procedures. *J Clin Microbiol* 28:2205-2209.
- Herzberg, M.C. 1996. Platelet-streptococcal interactions in endocarditis. *Crit Rev Oral Biol Med* 7:222-236.
- Herzberg, M.C., K.L. Brintzenhofe, and C.C. Clawson. 1983. Cell-free released components of *Streptococcus sanguis* inhibit human platelet aggregation. *Infect Immun* 42:394-401.
- Herzberg, M.C., and M.W. Meyer. 1996. Effects of oral flora on platelets: possible consequences in cardiovascular disease. *J Periodontol* 67:1138-1142.
- Herzberg, M.C., A. Nobbs, L. Tao, A. Kilic, E. Beckman, A. Khammanivong, and Y. Zhang. 2005. Oral streptococci and cardiovascular disease: searching for the platelet aggregation-associated protein gene and mechanisms of *Streptococcus sanguis*-induced thrombosis. *J Periodontol* 76:2101-2105.
- Hildebrand, A., M. Pohl, and S. Bhakdi. 1991. Staphylococcus aureus alpha-toxin. Dual mechanism of binding to target cells. *J Biol Chem* 266:17195-17200.
- Homma, S., and C. Grahame-Clarke. 2003. Toward reducing embolic complications from endocarditis. *J Am Coll Cardiol* 42:781-783.
- Ikigai, H., and T. Nakae. 1985. Conformational alteration in alpha-toxin from *Staphylococcus aureus* concomitant with the transformation of the water-soluble monomer to the membrane oligomer. *Biochem Biophys Res Commun* 130:175-181.
- Jakubovics, N.S., S.W. Kerrigan, A.H. Nobbs, N. Stromberg, C.J. van Dolleweerd, D.M. Cox, C.G. Kelly, and H.F. Jenkinson. 2005a. Functions of cell surface-anchored antigen I/II family and Hsa polypeptides in interactions of *Streptococcus gordonii* with host receptors. *Infect Immun* 73:6629-6638.
- Jakubovics, N.S., N. Stromberg, C.J. van Dolleweerd, C.G. Kelly, and H.F. Jenkinson. 2005b. Differential binding specificities of oral streptococcal antigen I/II family adhesins for human or bacterial ligands. *Mol Microbiol* 55:1591-1605.
- Johnson, M.K., D. Boese-Marrazzo, and W.A. Pierce, Jr. 1981. Effects of pneumolysin on human polymorphonuclear leukocytes and platelets. *Infect Immun* 34:171-176.
- Keane, C., H. Petersen, K. Reynolds, D.K. Newman, D. Cox, H.F. Jenkinson, P.J. Newman, and S.W. Kerrigan. 2010a. Mechanism of outside-in  $\alpha$ IIb $\beta$ 3-mediated activation of human platelets by the colonizing bacterium, *Streptococcus gordonii*. *Arterioscler Thromb Vasc Biol* 30:2408-2415.
- Keane, C., D. Tilley, A. Cunningham, A. Smolenski, A. Kadioglu, D. Cox, H.F. Jenkinson, and S.W. Kerrigan. 2010b. Invasive *Streptococcus pneumoniae* trigger platelet activation via Toll-like receptor 2. *J Thromb Haemost* 8:2757-2765.
- Kerrigan, S.W., N. Clarke, A. Loughman, G. Meade, T.J. Foster, and D. Cox. 2008. Molecular basis for *Staphylococcus aureus*-mediated platelet aggregate formation under arterial shear in vitro. *Arterioscler Thromb Vasc Biol* 28:335-340.


- Kerrigan, S.W., I. Douglas, A. Wray, J. Heath, M.F. Byrne, D. Fitzgerald, and D. Cox. 2002. A role for glycoprotein Ib in *Streptococcus sanguis*-induced platelet aggregation. *Blood* 100:509-516.
- Kerrigan, S.W., N.S. Jakubovics, C. Keane, P. Maguire, K. Wynne, H.F. Jenkinson, and D. Cox. 2007. Role of *Streptococcus gordonii* surface proteins SspA/SspB and Hsa in platelet function. *Infect Immun* 75:5740-5747.
- Lotz, S., A. Starke, C. Ziemann, S. Morath, T. Hartung, W. Solbach, and T. Laskay. 2006. Beta-lactam antibiotic-induced release of lipoteichoic acid from *Staphylococcus aureus* leads to activation of neutrophil granulocytes. *Ann Clin Microbiol Antimicrob* 5:15.
- Loughman, A., J.R. Fitzgerald, M.P. Brennan, J. Higgins, R. Downer, D. Cox, and T.J. Foster. 2005. Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by *Staphylococcus aureus* clumping factor A. *Mol Microbiol* 57:804-818.
- Lourbakos, A., Y.P. Yuan, A.L. Jenkins, J. Travis, P. Andrade-Gordon, R. Santulli, J. Potempa, and R.N. Pike. 2001. Activation of protease-activated receptors by gingipains from *Porphyromonas gingivalis* leads to platelet aggregation: a new trait in microbial pathogenicity. *Blood* 97:3790-3797.
- Manohar, M., S.K. Maheswaran, S.P. Frommes, and R.K. Lindorfer. 1967. Platelet damaging factor, a fifth activity of staphylococcal alpha-toxin. *J Bacteriol* 94:224-231.
- Marcus, A.J., H.L. Ullman, and L.B. Safier. 1972. Studies on human platelet gangliosides. *J Clin Invest* 51:2602-2612.
- Matsumoto-Nakano, M., M. Tsuji, S. Inagaki, K. Fujita, K. Nagayama, R. Nomura, and T. Ooshima. 2009. Contribution of cell surface protein antigen c of *Streptococcus mutans* to platelet aggregation. *Oral Microbiol Immunol* 24:427-430.
- McAleese, F.M., E.J. Walsh, M. Sieprawska, J. Potempa, and T.J. Foster. 2001. Loss of clumping factor B fibrinogen binding activity by *Staphylococcus aureus* involves cessation of transcription, shedding and cleavage by metalloprotease. *J Biol Chem* 276:29969-29978.
- McNicol, A., R. Zhu, R. Pesun, C. Pampolina, E.C. Jackson, G.H. Bowden, and T. Zelinski. 2006. A role for immunoglobulin G in donor-specific *Streptococcus sanguis*-induced platelet aggregation. *Thromb Haemost* 95:288-293.
- Meenan, N.A., L. Visai, V. Valtulina, U. Schwarz-Linek, N.C. Norris, S. Gurusiddappa, M. Hook, P. Speziale, and J.R. Potts. 2007. The tandem beta-zipper model defines high affinity fibronectin-binding repeats within *Staphylococcus aureus* FnBPA. *J Biol Chem* 282:25893-25902.
- Mercier, R.-C., R.M. Dietz, J.L. Mazzola, A.S. Bayer, and M.R. Yeaman. 2004. Beneficial Influence of Platelets on Antibiotic Efficacy in an In Vitro Model of *Staphylococcus aureus*-Induced Endocarditis. *Antimicrob. Agents Chemother.* 48:2551-2557.
- Miajlovic, H., A. Loughman, M. Brennan, D. Cox, and T.J. Foster. 2007. Both complement- and fibrinogen-dependent mechanisms contribute to platelet aggregation mediated by *Staphylococcus aureus* clumping factor B. *Infect Immun* 75:3335-3343.
- Miajlovic, H., M. Zapotoczna, J.A. Geoghegan, S.W. Kerrigan, P. Speziale, and T.J. Foster. 2010. Direct interaction of iron-regulated surface determinant IsdB of *Staphylococcus aureus* with the GPIIb/IIIa receptor on platelets. *Microbiology* 156:920-928.
- Mitchell, J., I.R. Siboo, D. Takamatsu, H.F. Chambers, and P.M. Sullam. 2007. Mechanism of cell surface expression of the *Streptococcus mitis* platelet binding proteins PblA and PblB. *Mol Microbiol* 64:844-857.

- Morath, S., S. von Aulock, and T. Hartung. 2005. Structure/function relationships of lipoteichoic acids. *J Endotoxin Res* 11:348-356.
- Moreillon, P., Y.A. Que, and A.S. Bayer. 2002. Pathogenesis of streptococcal and staphylococcal endocarditis. *Infect Dis Clin North Am* 16:297-318.
- Moreillon, P.P., and Y.-A. Que. 2004. Infective endocarditis. *The Lancet* 363:139-149.
- Motto, D.G., A.K. Chauhan, G. Zhu, J. Homeister, C.B. Lamb, K.C. Desch, W. Zhang, H.M. Tsai, D.D. Wagner, and D. Ginsburg. 2005. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. *J Clin Invest* 115:2752-2761.
- Munro, C.L., and F.L. Macrina. 1993. Sucrose-derived exopolysaccharides of *Streptococcus mutans* V403 contribute to infectivity in endocarditis. *Mol Microbiol* 8:133-142.
- Naber, C.K., and R. Erbel. 2007. Infective endocarditis with negative blood cultures. *International Journal of Antimicrobial Agents* 30:32-36.
- Naito, M., E. Sakai, Y. Shi, H. Ideguchi, M. Shoji, N. Ohara, K. Yamamoto, and K. Nakayama. 2006. Porphyromonas gingivalis-induced platelet aggregation in plasma depends on Hgp44 adhesin but not Rgp proteinase. *Mol Microbiol* 59:152-167.
- Nguyen, T., B. Ghebrehiwet, and E.I. Peerschke. 2000. Staphylococcus aureus protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets. *Infect Immun* 68:2061-2068.
- Nishimura, R.A., B.A. Carabello, D.P. Faxon, M.D. Freed, B.W. Lytle, P.T. O'Gara, R.A. O'Rourke, and P.M. Shah. 2008. ACC/AHA 2008 Guideline Update on Valvular Heart Disease: Focused Update on Infective Endocarditis. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* CIRCULATIONAHA.108.190377.
- Nobbs, A.H., R.J. Lamont, and H.F. Jenkinson. 2009. Streptococcus adherence and colonization. *Microbiol Mol Biol Rev* 73:407-450, Table of Contents.
- Nobbs, A.H., B.H. Shearer, M. Drobni, M.A. Jepson, and H.F. Jenkinson. 2007. Adherence and internalization of *Streptococcus gordonii* by epithelial cells involves beta1 integrin recognition by SspA and SspB (antigen I/II family) polypeptides. *Cell Microbiol* 9:65-83.
- O'Seaghdha, M., C.J. van Schooten, S.W. Kerrigan, J. Emsley, G.J. Silverman, D. Cox, P.J. Lenting, and T.J. Foster. 2006. Staphylococcus aureus protein A binding to von Willebrand factor A1 domain is mediated by conserved IgG binding regions. *FEBS J* 273:4831-4841.
- Ohkuni, H., Y. Todome, Y. Watanabe, S. Kotani, and Y. Kimura. 1997. Purification and partial characterization of a novel human platelet aggregation factor in the extracellular products of *Streptococcus mitis*, strain Nm-65. *Adv Exp Med Biol* 418:689-693.
- Pampolina, C., and A. McNicol. 2005. Streptococcus sanguis-induced platelet activation involves two waves of tyrosine phosphorylation mediated by FcgammaRIIA and alphaIIb beta3. *Thromb Haemost* 93:932-939.
- Pawar, P., P.K. Shin, S.A. Mousa, J.M. Ross, and K. Konstantopoulos. 2004. Fluid shear regulates the kinetics and receptor specificity of Staphylococcus aureus binding to activated platelets. *J Immunol* 173:1258-1265.
- Petersen, H.J., C. Keane, H.F. Jenkinson, M.M. Vickerman, A. Jesionowski, J.C. Waterhouse, D. Cox, and S.W. Kerrigan. 2010. Human platelets recognize a novel surface

- protein, PadA, on *Streptococcus gordonii* through a unique interaction involving fibrinogen receptor GPIIb/IIIa. *Infect Immun* 78:413-422.
- Plummer, C., H. Wu, S.W. Kerrigan, G. Meade, D. Cox, and C.W. Ian Douglas. 2005. A serine-rich glycoprotein of *Streptococcus sanguis* mediates adhesion to platelets via GPIb. *Br J Haematol* 129:101-109.
- Prakobphol, A., F. Xu, V.M. Hoang, T. Larsson, J. Bergstrom, I. Johansson, L. Frangsmyr, U. Holmskov, H. Leffler, C. Nilsson, T. Boren, J.R. Wright, N. Stromberg, and S.J. Fisher. 2000. Salivary agglutinin, which binds *Streptococcus mutans* and *Helicobacter pylori*, is the lung scavenger receptor cysteine-rich protein gp-340. *J Biol Chem* 275:39860-39866.
- Raibaud, S., U. Schwarz-Linek, J.H. Kim, H.T. Jenkins, E.R. Baines, S. Gurusiddappa, M. Hook, and J.R. Potts. 2005. *Borrelia burgdorferi* binds fibronectin through a tandem beta-zipper, a common mechanism of fibronectin binding in staphylococci, streptococci, and spirochetes. *J Biol Chem* 280:18803-18809.
- Ramboarina, S., J.A. Garnett, M. Zhou, Y. Li, Z. Peng, J.D. Taylor, W.C. Lee, A. Bodey, J.W. Murray, Y. Alguel, J. Bergeron, B. Bardiaux, E. Sawyer, R. Isaacson, C. Tagliaferri, E. Cota, M. Nilges, P. Simpson, T. Ruiz, H. Wu, and S. Matthews. 2010. Structural insights into serine-rich fimbriae from Gram-positive bacteria. *J Biol Chem* 285:32446-32457.
- Rasmussen, M., D. Johansson, S.K. Sobirk, M. Morgelin, and O. Shannon. 2010. Clinical isolates of *Enterococcus faecalis* aggregate human platelets. *Microbes Infect* 12:295-301.
- Rasmussen, R.V., U. Host, M. Arpi, C. Hassager, H.K. Johansen, E. Korup, H.C. Schonheyder, J. Berning, S. Gill, F.S. Rosenvinge, V.G. Fowler, Jr., J.E. Moller, R.L. Skov, C.T. Larsen, T.F. Hansen, S. Mard, J. Smit, P.S. Andersen, and N.E. Bruun. 2011. Prevalence of infective endocarditis in patients with *Staphylococcus aureus* bacteraemia: the value of screening with echocardiography. *Eur J Echocardiogr* 12:414-420.
- Ruggeri, Z.M. 2009. Platelet adhesion under flow. *Microcirculation* 16:58-83.
- Schwarz, S., A. Bottner, H.M. Hafez, C. Kehrenberg, M. Kietzmann, D. Klarmann, G. Klein, P. Krabisch, T. Kuhn, G. Luhofer, A. Richter, W. Traeder, K.H. Waldmann, J. Wallmann, and C. Werckenthin. 2003. [Antimicrobial susceptibility testing of bacteria isolated from animals: methods for in-vitro susceptibility testing and their suitability with regard to the generation of the most useful data for therapeutic applications]. *Berl Munch Tierarztl Wochenschr* 116:353-361.
- Semple, J., and J. Freedman. 2010. Platelets and innate immunity. *Cellular and Molecular Life Sciences* 67:499-511.
- Seo, H.S., Y.Q. Xiong, J. Mitchell, R. Seepersaud, A.S. Bayer, and P.M. Sullam. 2010. Bacteriophage lysin mediates the binding of *Streptococcus mitis* to human platelets through interaction with fibrinogen. *PLoS Pathog* 6:
- Sheu, J.R., G. Hsiao, C. Lee, W. Chang, L.W. Lee, C.H. Su, and C.H. Lin. 2000a. Antiplatelet activity of *Staphylococcus aureus* lipoteichoic acid is mediated through a cyclic AMP pathway. *Thromb Res* 99:249-258.
- Sheu, J.R., C.R. Lee, C.H. Lin, G. Hsiao, W.C. Ko, Y.C. Chen, and M.H. Yen. 2000b. Mechanisms involved in the antiplatelet activity of *Staphylococcus aureus* lipoteichoic acid in human platelets. *Thromb Haemost* 83:777-784.



- Siboo, I.R., H.F. Chambers, and P.M. Sullam. 2005. Role of SraP, a Serine-Rich Surface Protein of *Staphylococcus aureus*, in binding to human platelets. *Infect Immun* 73:2273-2280.
- Siegel, I., and S. Cohen. 1964. Action of Staphylococcal Toxin on Human Platelets. *J Infect Dis* 114:488-502.
- Skaar, E.P., and O. Schneewind. 2004. Iron-regulated surface determinants (Isd) of *Staphylococcus aureus*: stealing iron from heme. *Microbes Infect* 6:390-397.
- Sullam, P.M., A.S. Bayer, W.M. Foss, and A.L. Cheung. 1996. Diminished platelet binding in vitro by *Staphylococcus aureus* is associated with reduced virulence in a rabbit model of infective endocarditis. *Infect Immun* 64:4915-4921.
- Takahashi, Y., K. Konishi, J.O. Cisar, and M. Yoshikawa. 2002. Identification and characterization of hsa, the gene encoding the sialic acid-binding adhesin of *Streptococcus gordonii* DL1. *Infect Immun* 70:1209-1218.
- Takahashi, Y., A. Yajima, J.O. Cisar, and K. Konishi. 2004. Functional analysis of the *Streptococcus gordonii* DL1 sialic acid-binding adhesin and its essential role in bacterial binding to platelets. *Infect Immun* 72:3876-3882.
- Takamatsu, D., B.A. Bensing, H. Cheng, G.A. Jarvis, I.R. Siboo, J.A. Lopez, J.M. Griffiss, and P.M. Sullam. 2005. Binding of the *Streptococcus gordonii* surface glycoproteins GspB and Hsa to specific carbohydrate structures on platelet membrane glycoprotein Ibalpha. *Mol Microbiol* 58:380-392.
- Valeva, A., A. Weisser, B. Walker, M. Kehoe, H. Bayley, S. Bhakdi, and M. Palmer. 1996. Molecular architecture of a toxin pore: a 15-residue sequence lines the transmembrane channel of staphylococcal alpha-toxin. *EMBO J* 15:1857-1864.
- Vanhoorelbeke, K., H. Ulrichs, G. Van de Walle, A. Fontayne, and H. Deckmyn. 2007. Inhibition of platelet glycoprotein Ib and its antithrombotic potential. *Curr Pharm Des* 13:2684-2697.
- Varki, A. 1994. Selectin ligands. *Proc Natl Acad Sci U S A* 91:7390-7397.
- Viisoreanu, D., R. Polanowska-Grabowska, S. Suttitanamongkol, T.G. Obrug, and A.R. Gear. 2000. Human platelet aggregation is not altered by Shiga toxins 1 or 2. *Thromb Res* 98:403-410.
- Ward, J.R., L. Bingle, H.M. Judge, S.B. Brown, R.F. Storey, M.K. Whyte, S.K. Dower, D.J. Buttle, and I. Sabroe. 2005. Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. *Thromb Haemost* 94:831-838.
- Wu, H., M. Zeng, and P. Fives-Taylor. 2007. The glycan moieties and the N-terminal polypeptide backbone of a fimbria-associated adhesin, Fap1, play distinct roles in the biofilm development of *Streptococcus parasanguinis*. *Infect Immun* 75:2181-2188.
- Yajima, A., Y. Takahashi, and K. Konishi. 2005. Identification of platelet receptors for the *Streptococcus gordonii* DL1 sialic acid-binding adhesin. *Microbiol Immunol* 49:795-800.
- Youssefian, T., A. Drouin, J.M. Masse, J. Guichard, and E.M. Cramer. 2002. Host defense role of platelets: engulfment of HIV and *Staphylococcus aureus* occurs in a specific subcellular compartment and is enhanced by platelet activation. *Blood* 99:4021-4029.
- Zahringer, U., B. Lindner, S. Inamura, H. Heine, and C. Alexander. 2008. TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. *Immunobiology* 213:205-224.



## **Endocarditis**

Edited by Prof. Francisco Ramón Breijo-Márquez

ISBN 978-953-307-901-1

Hard cover, 152 pages

**Publisher** InTech

**Published online** 20, January, 2012

**Published in print edition** January, 2012

Endocarditis is a disease that occurs as a result of the inflammation of the endocardium. It is an inflammatory process located in the inner lining of the cardiac chambers and native or prosthetic valves. It is characterized by colonization or invasion of the heart valve vegetations composed of platelets forming, fibrin and microcolonies of microorganisms, and occasionally of inflammatory cells. Other structures may also be affected, such as the interventricular septum, chordae tendineae, the mural endocardium or even intra-cardiac implants. The book covers, with scientific rigour, the most prevalent causes and current treatments of endocarditis, as well as the cases when the organs remote from the heart are affected by this disease.

### **How to reference**

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Steven W. Kerrigan and Dermot Cox (2012). Platelet-Bacterial Interactions as Therapeutic Targets in Infective Endocarditis, Endocarditis, Prof. Francisco Ramón Breijo-Márquez (Ed.), ISBN: 978-953-307-901-1, InTech, Available from: <http://www.intechopen.com/books/endocarditis/platelet-bacterial-interactions-as-therapeutic-targets-in-infective-endocarditis>

**INTECH**  
open science | open minds

#### **InTech Europe**

University Campus STeP Ri  
Slavka Krautzeka 83/A  
51000 Rijeka, Croatia  
Phone: +385 (51) 770 447  
Fax: +385 (51) 686 166  
[www.intechopen.com](http://www.intechopen.com)

#### **InTech China**

Unit 405, Office Block, Hotel Equatorial Shanghai  
No.65, Yan An Road (West), Shanghai, 200040, China  
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元  
Phone: +86-21-62489820  
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen